ArticleThe journal of allergy and clinical immunology. Global2024

A 13.2 mg epinephrine intranasal spray demonstrates comparable pharmacokinetics, pharmacodynamics, and safety to a 0.3 mg epinephrine autoinjector.

David A Dworaczyk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.